Vitamin D Fails In Major Woman’s Study: Findings Represent Results Of First Large Scale Trials of Vitamin D and Calcium For Prevention Of Bone Loss And Cancer.

The Women’s Health Initiative ran one of the largest long term trials we have on vitamin D and calcium supplementation in postmenopausal women, and when the bone and cancer arms reported out, the headlines wrote themselves: vitamin D failed. Over 15,000 women were followed. The hip fracture numbers moved a little. The colon cancer numbers did not budge. End of story, as far as the news cycle was concerned.

I read the actual paper. Here is what almost nobody in the lay press bothered to mention.

The dose was set up to fail

The trial used 400 IU of vitamin D3 per day, paired with 1 gram of calcium carbonate. Four hundred IU is roughly what shows up in a generic adult multivitamin. It is not a therapeutic dose. Most of the clinical work that has shown skeletal and metabolic benefit from vitamin D uses 2,000 to 5,000 IU daily, and dose adjusts based on a 25 hydroxy vitamin D blood level. The WHI design did neither.

On top of that, the calcium source was carbonate, which is the cheapest and worst absorbed form of calcium on the shelf. If you wanted to design a study to prove a supplement does not work, you would pick a low dose, the wrong form, and no biomarker check. That is more or less what happened here.

What the data still showed

Even with an underpowered dose, the WHI saw a modest reduction in hip fractures. Hip fracture in an older adult is not a small event. It is a common path to losing independence and, in many cases, a path that ends within a year. A modest reduction at a low dose suggests something real is going on. Push the dose into the studied range and check blood levels, and the signal would almost certainly look stronger.

On colon cancer the trial showed nothing. Honestly, I would not expect 400 IU to move colon cancer either. The observational data that put vitamin D on the colon cancer map are mostly tied to plasma 25 hydroxy D levels in the 40 to 60 ng/mL range. Almost no one gets to that range on 400 IU a day. The trial was not testing what the headline claimed it was testing.

What the study did not measure

The single biggest weakness of the WHI on this question is that researchers did not measure 25 hydroxy vitamin D levels in the participants. Without that, you cannot say who was actually replete, who was still deficient at the end of the trial, and who responded to supplementation. Vitamin D is a hormone with wildly variable absorption and tissue conversion. Two people on the same dose can land 30 ng/mL apart. A real trial measures the input and the output. This one only measured the input.

It is also worth noting that we heard a lot about theoretical vitamin D toxicity in the years after this paper came out. In thirty years of medicine I have seen exactly one case of true vitamin D toxicity, and many, many cases of deficiency. Toxicity is rare and almost always tied to industrial dosing errors. Deficiency is the everyday problem.

What to do with this

If you are taking vitamin D and want to know whether it is doing anything for you:

• Get a 25 hydroxy vitamin D blood test once or twice a year. Most labs run it cheap.
• Aim for a plasma level in the 45 to 70 ng/mL range, which is where most of the bone, immune, and metabolic data line up.
• If you are below that, 2,000 to 5,000 IU of D3 daily is a reasonable adult range to start with, paired with K2 and adequate magnesium, then retest in three months.
• Do not use calcium carbonate as your calcium source. Calcium citrate, calcium malate, or food sources absorb far better.

The WHI did not prove vitamin D does not work. It proved that a small dose of D paired with a poorly absorbed calcium, with no biomarker checks, produces a small effect. That is not the same thing.

— Doc